Objective: To identify potential genetic modifiers contributing to the phenotypic variability that is detected in patients with repeat expansions in chromosome 9 open reading frame 72 (C9ORF72), we investigated the frequency of these expansions in a cohort of 334 subjects previously found to carry mutations in genes known to be associated with a spectrum of neurodegenerative diseases.
assessed the frequency of these expansions in a heterogeneous cohort of 334 subjects previously found to carry pathogenic mutations in genes associated with neurodegenerative diseases.
METHODS Subject selection. Two study cohorts were analyzed for C9ORF72 repeat expansions. Our initial study cohort consisted of 149 probands with mutations in genes known to be associated with a spectrum of neurodegenerative diseases (table 1) . These subjects were of North American descent and obtained through the Mayo Clinic (n 5 84), University of Western Ontario (n 5 Based on the identification of C9ORF72 repeat expansions in progranulin (GRN) and microtubule-associated protein tau (MAPT) mutation carriers in our initial study cohort, we selected a follow-up cohort with additional GRN and MAPT mutation carriers. This follow-up cohort consisted of 102 family members of probands from our initial study cohort, and 83 subjects from 68 new families of North American and Italian origin. These latter families were provided by other collaborators at IRCCS Istituto Centro San Giovanni di Dio-Fatebenefratelli (n 5 68), University of Pennsylvania School of Medicine (n 5 3), Northwestern University Feinberg School of Medicine (n 5 2, M.M.), National Institute of Neurological Disorders and Stroke and NIH (n 5 3), and University of Washington School of Medicine (n 5 7).
Standard protocol approvals, registrations, and patient consents. All subjects agreed to be in the study, and biological samples were obtained after informed consent with ethical committee approval from the respective institutions.
Genetic analysis. The GGGGCC repeat in C9ORF72 was assessed using a 2-step protocol. 1 Briefly, genomic DNA was PCR-amplified with genotyping primers and one fluorescently labeled primer, followed by fragment length analysis on an ABI3730 DNA analyzer (Applied Biosystems, Foster City, CA) and visualized using GeneMapper v4.0 software (Applied Biosystems). For individuals who were shown to be homozygous for C9ORF72 repeats, we performed a repeat-primed PCR, and PCR products were analyzed with an ABI3730 DNA Analyzer and GeneMapper software. A characteristic stutter pattern was considered evidence of a C9ORF72 repeat expansion.
Southern blot. Southern blotting was performed as described by DeJesus-Hernandez et al., 1 with minor modifications. DNA was isolated from frozen frontal cortex, temporal cortex, and cerebellum. A total of 10 mg of genomic DNA was digested with XbaI, and electrophoresed in an agarose gel. DNA was then transferred to a positively charged nylon membrane (Roche, Penzberg, Germany.) and cross-linked by UV irradiation. After prehybridization in digoxigenin (DIG) EasyHyb solution (Roche), hybridization with a DIGlabeled probe in hybridization solution was performed. Anti-DIG antibody (1:10,000; Roche) was used to detect the probe, which was subsequently visualized with CDP-star substrate (Roche) on X-ray film after an exposure of 30 to 60 minutes.
Immunohistochemistry. Immunohistochemistry was performed for 3 patients in a blinded fashion, including patient F with double mutations, and for 2 patients from our initial study cohort with only GRN mutations (p.Thr382SerfsX30, c.IVS111G.A). Immunohistochemistry for TAR DNA-binding protein 43 (TDP-43) (1:2,500, rabbit polyclonal, Mayo Clinic), 8 repeat-associated non-ATG translation peptides (C9RANT, Rb5823, 1:5,000), 9 and p62 (1:1,000, lck ligand; BD Bioscience, Franklin Lakes, NJ) was performed on 5-mm-thick sections from the frontal cortex, hippocampus, and cerebellum. These sections were cut from formalin-fixed paraffin-embedded blocks, deparaffinized in xylene, rehydrated in a graded series of ethanol, and washed in distilled water. DAKO Autostainer Plus (DAKO, Carpinteria, CA) and DAKO EnVision1 System-horseradish peroxidase (diaminobenzidine) were used to process stains. To block nonspecific binding, normal goat serum (1:20 in Tris-buffered saline and Tween 20; Sigma, St. Louis, MO) was added to slides before the primary antibody.
RESULTS Within our initial study cohort of 149 subjects with known pathogenic mutations in neurodegenerative disease genes, we identified 3 individuals with an additional C9ORF72 repeat expansion (2.0%). These expansions were present in 2 subjects with a GRN mutation (p.C466LfsX46 [c.1395_1396insC], p.C31LfsX35 [c.90_91insCTGC]) and in one subject with a MAPT mutation (p.P301L [c.902C.T]). In our follow-up cohort of 185 subjects with GRN or MAPT mutations, we detected another individual with both a GRN mutation (p.R493X [c.1477C.T]) and a C9ORF72 repeat expansion (0.5%).
In total, we therefore identified double mutations in 4 of 334 subjects (1.2%) or 4 of 217 families (1.8%) studied. The C9ORF72 repeat expansions were present in 3 of 204 subjects from our GRN subgroup (1.5% [or 2.0% of 152 GRN families]), and in 1 of 94 subjects from our MAPT subgroup (1.1% [or 3.3% of 30 MAPT families]). Importantly, these subjects with double mutations all showed a behavioral phenotype, and they did not demonstrate signs of MND. Furthermore, our subjects with double mutations appeared to be relatively young when they presented with behavioral impairment (53 years or younger; table 2), as compared with the mean of our initial and follow-up cohorts (56 and 58 years; table 1). All subjects with double mutations had a positive family history for dementia, and interestingly, 2 of 4 of these subjects had family members with MND (50%). Chromatograms and electropherograms of identified subjects are displayed in figure 1 , and their pedigrees are shown in figure e-1 on the Neurology ® Web site at www.neurology.org. DNA of relatives was unavailable; therefore, cosegregation of the mutations in families could not be assessed.
Brain autopsy material, however, was available for one of the identified subjects (F). We obtained DNA from the frontal cortex, temporal cortex, and cerebellum, and performed a Southern blot (in duplicate). Patient F clearly demonstrated an expanded repeat (figure 2), as shown by a smear of high-molecular-weight bands, suggestive for somatic repeat instability. 1 The longest repeat expansion of this double mutant was present in the frontal cortex and was estimated to be , or an unknown diagnosis (n 5 6), and in our follow-up cohort, we included patients with multiple system atrophy (n 5 1), corticobasal degeneration (n 5 8), FTD/MND (n 5 1), Alzheimer disease (n 5 5), Lewy body disease (n 5 3), FTD with parkinsonism (n 5 27), mild cognitive impairment (n 5 2), dementia not otherwise specified (n 5 1), or an unknown disease (n 5 11). b For age at onset, age at death, and disease duration, standard errors are shown in parentheses. approximately 23 kb in size, bearing more than 3,000 hexanucleotide repeats.
Immunohistochemistry was also performed for patient F and 2 control patients with only GRN mutations (figure 3). Patient F showed type A TDP-43 pathology, including neuronal cytoplasmic inclusions and neuritic pathology. In addition, p62 and C9RANT immunohistochemistry showed many neuronal cytoplasmic inclusions, consistent with a mutation in C9ORF72. Blinded investigations of all 3 patients successfully identified the double mutant; whereas all patients demonstrated type A neuronal TDP-43 inclusions, 10,11 only patient F showed these inclusions in combination with C9RANT immunoreactivity, and ubiquitin-positive, TDP-43-negative, neuronal cytoplasmic inclusions in the cerebellum, which have been shown to be unique for C9ORF72 repeat expansion carriers. 9, 12, 13 Patient F, therefore, demonstrated mixed pathology with characteristics of both GRN mutations and C9ORF72 expansions.
DISCUSSION In our present study, we discovered C9ORF72 repeat expansions in 4 of 217 families with previously identified mutations in neurodegenerative disease genes. Since the identification of C9ORF72 expansions, 1,2 researchers all over the world have reported case series with expansion frequencies. 5 On average, these expansions appear to account for 34% of familial MND cases and 26% of familial FTD cases. 5 They have, however, also been detected in control subjects; for instance, they were present in 4 of 4,368 control subjects of American and Italian descent. 5 Hence, the expansion frequency is significantly higher in our study population than in control subjects of the same origin (1.8% vs 0.1%: p value 5 0.0003, Fisher exact test). To date, the sizes of C9ORF72 repeat expansions in brain are largely unknown. Southern blots have proven to be challenging, and good-sized well-characterized cohorts have not been assessed to determine expansion sizes in brain. A recent study did investigate 57 patients with a range of neurodegenerative diseases, and demonstrated great variability in repeat sizes and smear morphologies, but this study focused on blood.
14 Thus far, brain tissues of only a few patients have been investigated, demonstrating sizes between approximately 600 and 4,000 repeats. 1, [14] [15] [16] [17] [18] [19] [20] We were able to perform a Southern blot for one of our double mutation carriers, patient F, and detected more than 3,000 hexanucleotide repeats. Our findings therefore indicate that this double mutation carrier has a long repeat expansion, in the same range as other patients with C9ORF72 expansions. The function of C9ORF72 is presently unknown, although recent reports have suggested that C9ORF72 belongs to a group of DENN (differentially expressed in normal and neoplasia) proteins, which are GEFs (guanosine diphosphate/guanosine triphosphate exchange factors) that activate Rab-GTPase switches and regulate vesicular trafficking processes. 21, 22 Consequently, repeat expansions in C9ORF72 could result in a loss of function and impair these processes. However, an RNAmediated gain-of-function mechanism could also contribute to disease due to generation of toxic RNA foci. 1 Furthermore, recently it was revealed that transcripts of patients with C9ORF72 repeat expansions are also prone to non-ATG translation. 9, 13 This unconventional method of translation can cause an accumulation of poly(glycineproline), poly(glycine-alanine), or poly(glycine-arginine) peptides in neurons throughout the CNS, and result in neuropathology specific to C9ORF72-associated MND and/or FTD. 9 In our present study, we have shown that one of our subjects with double mutations, patient F, exhibited C9RANT immunoreactivity, consistent with these novel reports. Patient F also harbored ubiquitin-positive, TDP-43-negative, neuronal cytoplasmic inclusions in the cerebellum, which have been shown to be typical for C9ORF72 repeat expansions. 12 In addition, patient F demonstrated TDP-43 type A pathology, characteristic for GRN mutations 3, 10, 11, 23 ; thus, this double mutation carrier displayed pathology distinctive for both C9ORF72 expansions and GRN mutations.
Interestingly, 2 patients have already been described with both C9ORF72 repeat expansions and a GRN variant (p.Y294C), 24 or a MAPT variant (p.A239T). 6 The p.Y294C GRN variant is novel, and has not been detected in other patients or in controls; it was present in a patient with behavioral variant FTD and it is predicted to be damaging. 24 The p.A239T MAPT variant was also identified in a patient with behavioral variant FTD. 6 She had 2 brothers with C9ORF72 expansions without the MAPT variant, who demonstrated signs of MND. The index case showed mixed pathology with both tauopathy and ubiquitin-positive, TDP-43-negative, neuronal cytoplasmic inclusions in the cerebellum. Nonetheless, accumulation of tau has also been reported in patients with only C9ORF72 expansions, and this accumulation could have resulted from disrupted protein degradation that favors accumulation of multiple different proteins, including tau. 25 Although the pathogenicity of the p.Y294C GRN variant and the p.A239T MAPT variant are not entirely clear, the 4 subjects that we identified with C9ORF72 expansions do harbor well-known pathogenic FTDassociated mutations. In tables e-1 and e-2, we have provided a detailed overview of more than 80 families carrying these relatively common mutations. Worldwide, the p.C466LfsX46 mutation accounts for 0.4% of all families with GRN mutations, the p.R493X mutation accounts for 18.6%, and the p.C31LfsX35 mutation accounts for 2.6%; the p.P301L mutation is present in 23.9% of families with MAPT mutations (http://www. molgen.ua.ac.be/FTDmutations/). Therefore, these 4 mutations are frequently detected, and are responsible for approximately 22% of patients with GRN mutations and approximately 24% of patients with MAPT mutations. Phenotypes of C9ORF72 repeat expansion carriers, in general, appear to differ from patients with mutations in GRN or MAPT. [26] [27] [28] [29] [30] It was shown that age at onset is earlier in patients with C9ORF72 expansions compared to patients with GRN mutations, [26] [27] [28] [29] but later compared to patients with MAPT mutations. [27] [28] [29] Moreover, MND is frequently detected in patients with C9ORF72 expansions, whereas signs of MND are scarce in patients with GRN or MAPT mutations. 26, [28] [29] [30] Behavioral variant FTD is the predominant phenotype of all 3 groups; primary progressive aphasia and corticobasal syndrome phenotypes are rare in patients with C9ORF72 expansions, and are more frequently detected in patients with GRN or MAPT mutations. 26, 29 The co-occurrence of C9ORF72 expansions and mutations in GRN or MAPT in patients with FTD could have several explanations. First, it could be argued that only C9ORF72 expansions are pathogenic, and that the GRN or MAPT mutations are rare benign variants or mere risk factors. This explanation, however, is not supported by ample studies that have revealed a strong association with FTD and indicated that they are definitely disease-causing mutations (tables e-1 and e-2). Second, it is possible that C9ORF72 expansions are not sufficient to develop disease, and that an additional mutation or environmental exposure is needed. This would provide an explanation for the increased frequency of C9ORF72 repeat expansions in cases with other genetic mutations. It is also in accordance with studies that have detected C9ORF72 expansions in control subjects, 5 and with studies that reported incomplete or age-dependent penetrance; approximately 50% of expansion carriers were clinically symptomatic by an age of 48 to 58 years, and almost full penetrance was seen at an age of 75 to 80 years. 27, 31, 32 This variable penetrance could be caused by differences in repeat sizes: long repeat sizes may represent clear pathogenic mutations, whereas intermediate sizes may act as risk factors that require a second factor, either genetic or environmental, to cause disease. Our current findings, however, oppose this explanation, while Southern blotting of one of our subjects with double mutations, patient F, revealed a relatively long repeat expansion, comparable to a patient carrying only a C9ORF72 repeat expansion. An age-dependent penetrance has also been reported for GRN, with only 50% of mutation carriers affected by the age of 60 years, and 90% of carriers affected at 70 years, 33 comparable to C9ORF72. The penetrance is more than 95% for MAPT. 34 It is therefore possible that one of the mutations observed in our double mutation carriers has not yet reached penetrance, and that the current symptoms are solely caused by the other mutation. Finally, it could be hypothesized that both C9ORF72 expansions and GRN or MAPT mutations are pathogenic, that each of these mutations independently causes disease, but that they act as disease modifiers when they co-occur. If we compare the mean age at which symptoms of behavioral impairment occurred between our double mutation carriers (mean: 48.8 6 3.0, n 5 4) and the remainder of our study population (mean: 57.0 6 0.73, n 5 235), then a one-tailed nonparametric Mann-Whitney test results in a p value of 0.0357. Because of the relatively small number of double mutation carriers, this difference is borderline significant, but there is clearly a tendency toward an earlier age at onset. Apart from this relatively young age at onset, all of our patients with double Comment: Double mutants of frontotemporal dementia genes-Simple co-occurrence?
In this international collaborative study searching for genetic modifiers in familial frontotemporal dementia (FTD), van Blitterswijk et al. 1 detected C9ORF72 repeat expansions in 1.8% of 217 North American and Italian families harboring progranulin (GRN) or microtubule-associated protein tau (MAPT) gene mutations. Since the GRN/MAPT mutations harbored by the families were different, it does not seem a mutation-specific effect. All double mutation carriers had an early disease onset, though the small number of double mutation carriers did not allow statistical comparisons with the FTD group without double mutations. Double mutation carriers showed a behavioral FTD presentation with no motor neuron signs, which are frequently seen in FTD families with expansion of the C9ORF72 gene. 2, 3 Knowing that expansions in the C9ORF72 gene can be rarely present in healthy controls (allele frequency 0.0004) and that GRN and MAPT mutations in aged healthy controls are generally absent, one conservative interpretation is that the presence of 2 FTD-associated mutations is merely coincidental and one of the 2 mutated genes, possibly C9ORF72, is not influencing the disease risk because of its reduced penetrance.
Another more plausible interpretation is that mutations in 2 of these 3 FTD genes could have some additive influence in disease expressivity. The researchers could not assess cosegregation of the mutations across the families. Although the number of double carriers does not allow us to make definite conclusions, the co-occurrence of 2 evidently pathogenic mutations could contribute to the pleiotropy observed in patients with C9ORF72 repeat expansions.
These results suggest that the damaging effects of mutated genes causing monogenic FTD are influenced by additional genetic and environmental factors, which can modify the genetic penetrance and expressivity. Since more information about oligogenic effects of FTD genes are needed, these results encourage us to be very cautious when assessing disease risk and advising family relatives.
mutations developed signs of behavioral impairment without MND, whereas combinations of C9ORF72 repeat expansions with MND-associated mutations in TARDBP (TAR DNA-binding protein), FUS/TLS (fused in sarcoma/translated in liposarcoma), and SOD1 (superoxide dismutase 1) have previously been detected in patients with MND without FTD. 4 However, numerous C9ORF72 expansion carriers without a second mutation in a known dementia gene also developed a pure behavioral variant FTD phenotype. In the future, detailed investigations of multiple patients in families carrying double mutations will be critical to determine the contribution of each mutation to disease.
While previous studies have provided evidence for an oligogenic basis of MND, 4 our present findings demonstrate that oligogenicity is not confined to MNDs, and that double mutations can be present in patients with FTD as well. Thus, it is important to realize that patients already diagnosed with mutations in FTD/MND-associated genes could also harbor more recently discovered C9ORF72 repeat expansions, and that they should not be excluded from further tests, which is also highly relevant for genetic counseling, both of patients and of their (unaffected) family members.
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